Screener
Supernus Pharmaceuticals SUPN Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Qelbree | 2,364 | 4,413 |
| ZURZUVAE | 82 | — |
| Early-stage programs and other expenses | 6,565 | 3,213 |
| Total external development program expenses | 27,678 | 16,432 |
| Internal employee-related expenses | 11,760 | 10,495 |
| Total research and development expenses | 39,438 | 26,927 |
| Other segment items(a) | 21,996 | 29,017 |
| Net loss | $(2,293) | $(11,827) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's business segments — R&D?
- Supernus Pharmaceuticals (SUPN) reported business segments — R&D of $39.44M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — R&D changed year-over-year?
- Supernus Pharmaceuticals's business segments — R&D increased by 46.5% year-over-year, from $26.93M to $39.44M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — R&D?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — R&D has grown at a 12.5% compound annual growth rate (CAGR), from $74.55M to $106.24M.
- What does business segments — R&D mean?
- Measures the total investment in discovering and developing new pharmaceutical products or improving existing ones. High levels of R&D spending indicate a commitment to long-term innovation and future growth potential.
Ask your AI about Supernus Pharmaceuticals's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude